Preclinical progression of new organic compounds with targeted biological activity (Q19981): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in 1 language: remove_english_label)
(‎Changed label, description and/or aliases in 1 language: translated_label)
label / enlabel / en
 
Preclinical progression of new organic compounds with targeted biological activity

Revision as of 09:18, 22 October 2020

Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Preclinical progression of new organic compounds with targeted biological activity
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    92,429,398.75 Czech koruna
    0 references
    3,697,175.95 Euro
    10 January 2020
    0 references
    108,740,469.26 Czech koruna
    0 references
    4,349,618.77 Euro
    10 January 2020
    0 references
    85.0 percent
    0 references
    1 August 2018
    0 references
    31 December 2022
    0 references
    Masarykova univerzita
    0 references
    0 references

    49°12'8.64"N, 16°36'28.44"E
    0 references

    49°11'55.68"N, 16°36'7.06"E
    0 references
    60200
    0 references
    Cílem projektu je optimalizace a preklinická profilace vybraných sloučenin s unikátní biologickou aktivitou s potenciálem vykázat terapeutickou účinnost při minimálních nežádoucích vedlejších účincích v oblasti onkologie a kardiologie. Náplní projektu bude mj. příprava širokého setu sloučenin a důkladné testování biologických a obzvláště farmakologických vlastností, včetně in vivo studií. Vzniklé duševní vlastnictví bude důsledně ošetřeno. Výsledky (TRL3)budou dopracovány s aplikačními firmami. a. (Czech)
    0 references
    The objective of the project is to optimise and preclinical profiling of selected compounds with unique biological activity with the potential to exhibit therapeutic efficacy in minimal side effects in oncology and cardiology. The project will include, inter alia, the preparation of a broad diet of compounds and a thorough testing of biological and particularly pharmacological properties, including in vivo studies. The resulting intellectual property will be thoroughly treated. The results (TRL3) will be finalised with application firmware. (English)
    0 references

    Identifiers

    CZ.02.1.01/0.0/0.0/16_025/0007381
    0 references